# STA-9090(Ganetespib) in Patients With Unresectable Stage III or Stage IV Melanoma

> **NCT01551693** · PHASE2 · TERMINATED · sponsor: **Dana-Farber Cancer Institute** · enrollment: 3 (actual)

## Conditions studied

- Melanoma

## Interventions

- **DRUG:** STA-9090

## Key facts

- **NCT ID:** NCT01551693
- **Lead sponsor:** Dana-Farber Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2011-09
- **Primary completion:** 2012-09
- **Final completion:** 2012-09
- **Target enrollment:** 3 (ACTUAL)
- **Why stopped:** due to weak accrual
- **Last updated:** 2017-04-12

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01551693

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01551693, "STA-9090(Ganetespib) in Patients With Unresectable Stage III or Stage IV Melanoma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01551693. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*